Contineum Therapeutics (CTNM) Net Equity Issued and Repurchased (2024 - 2025)
Contineum Therapeutics' (CTNM) quarterly Net Equity Issued and Repurchased came in at $99.2 million in Q4 2025, up 422.11% quarter-over-quarter from $19.0 million in Q3 2025.
Contineum Therapeutics (CTNM) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Contineum Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $99.2 million for Q4 2025.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $99.2 million in Q4 2025; TTM through Dec 2025 was $118.2 million, a 37906.43% increase from a year earlier, with the FY2025 full-year figure at $19.6 million, down 81.89% from the prior year.
- Net Equity Issued and Repurchased rose to $99.2 million in Q4 2025 per CTNM's latest filing, from $19.0 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $99.2 million in Q4 2025 and bottomed at $311000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Contineum Therapeutics | 536.56 Mn | 536.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 99.20 Mn |
| Dec 31, 2025 | 99.20 Mn |
| Sep 30, 2025 | 19.00 Mn |
| Sep 30, 2025 | 19.00 Mn |
| Jun 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 311,000.00 |